North East and North Cumbria
ICS Formulary
ICS Formulary
4 Central nervous system
04-07-03 Postherpetic neuralgia
| Capsaicin |
|
Formulary
|
|
 NTAG - Treatment Appraisal Decision Summary - Capsaicin (Qutenza) NTAG Pathway for the use of Qutenza (Capsaicin 8%) in the Neuropathic Pain Patient Group |
|
Links
MHRA Drug Safety Alert (Feb 2015): Drugs and driving: blood concentration limits set for certain drugs- MHRA Drug Safety Alert (Oct 2017): Gabapentin (Neurontin): risk of severe respiratory depression
- MHRA Drug Safety Update (Apr 2022): Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA Drug Safety Update (Feb 2021): Pregabalin (Lyrica): reports of severe respiratory depression
- NENC Palliative and End of Life Care Symptom Control Guidelines
- NICE CG173: Neuropathic pain in adults: pharmacological management in non-specialist settings
- NICE ES23: COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19
- NICE NG193: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain
- NICE NG41: Spinal injury: assessment and initial management
- NICE NG59: Low back pain and sciatica in over 16s: assessment and management
- NICE NG62: Cerebral palsy in under 25s: assessment and management
- NTAG - Treatment Appraisal Decision Summary - Capsaicin (Qutenza)
- NTAG Pathway for the use of Qutenza (Capsaicin 8%) in the Neuropathic Pain Patient Group
- TEWV - Medicines Optimisation – Interactive Guide
- TEWV Guidelines
- TEWV Safe Transfer of Prescribing Guidance